We are live on ! Find out more
ADIL

Adial Pharmaceuticals
ADIL

15 hedge funds and large institutions have $214K invested in Adial Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

205% more capital invested

Capital invested by funds: $70.2K → $214K (+$144K)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

0.02% more ownership

Funds ownership: 0.09% → 0.11% (+0.02%)

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$56.1K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$55.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$37.1K
4
TSS
Two Sigma Securities
New York
+$5.01K
5
PMG
Private Management Group
California
+$3.9K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$4.87K
2
Two Sigma Investments
Two Sigma Investments
New York
-$3.26K
3
HF
HRT Financial
New York
-$3.08K
4
Citigroup
Citigroup
New York
-$1.2K
5
SHIM
Stone House Investment Management
Pennsylvania
-$816
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$58K +$37.1K +3,811 +138%
Vanguard Group
2
Vanguard Group
Pennsylvania
$55.2K +$55.7K +5,715 +1,087%
Citadel Advisors
3
Citadel Advisors
Florida
$50.8K +$56.1K +5,752 New
MCM
4
Manchester Capital Management
Vermont
$17K – – –
BlackRock
5
BlackRock
New York
$9.82K – – –
UBS Group
6
UBS Group
Switzerland
$6.62K +$2.48K +254 +51%
TSS
7
Two Sigma Securities
New York
$4.54K +$5.01K +514 New
Jane Street
8
Jane Street
New York
$4.36K -$4.87K -500 -50%
PMG
9
Private Management Group
California
$3.54K +$3.9K +400 New
HF
10
HRT Financial
New York
$3K -$3.08K -316 -41%
SS
11
SBI Securities
Japan
$493 +$29 +3 +6%
TRCT
12
Tower Research Capital (TRC)
New York
$484 -$19 -2 -4%
Bank of America
13
Bank of America
North Carolina
$64 +$39 +4 +133%
Wells Fargo
14
Wells Fargo
California
$57 – – –
AWM
15
Abound Wealth Management
Tennessee
$10 – – –
Morgan Stanley
16
Morgan Stanley
New York
$3 – – –
Two Sigma Investments
17
Two Sigma Investments
New York
– -$3.26K -432 Closed
Citigroup
18
Citigroup
New York
– -$1.2K -159 Closed
SHIM
19
Stone House Investment Management
Pennsylvania
– -$816 -108 Closed

ADIL Hedge Fund Activity: Q3 2025 in Review

15 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q3 2025, worth a combined $214K — up 205% from $70.2K a quarter earlier.

Fund positioning in ADIL was balanced in Q3 2025: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 3 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $56.1K. The largest seller was Jane Street, cutting an estimated $4.87K.

  • 15 institutional investors held Adial Pharmaceuticals (ADIL) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $214K of Adial Pharmaceuticals stock for Q3 2025, up 205% quarter-over-quarter.
  • 3 funds opened new Adial Pharmaceuticals positions in Q3 2025 and 3 closed out, a net change of 0 holders.
  • The largest Adial Pharmaceuticals buyer in Q3 2025 was Citadel Advisors, an estimated $56.1K added.
  • The largest Adial Pharmaceuticals seller in Q3 2025 was Jane Street, an estimated $4.87K sold.

Based on aggregated 13F filings for Q3 2025.